Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey

Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic network

The past week was notable on both policy and infrastructure fronts, with the FDA formalizing a one-pivotal-trial default and emphasizing mechanistic, real-world, and model-based confirmative evidence, and Eli Lilly bringing online its in-house AI supercomputer in Indianapolis to support large-scale biology and chemistry models.

A newly launched U.S. bra…